REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, vol.66, no.6, pp.800-805, 2020 (Peer-Reviewed Journal)
Article / Article
REVISTA DA ASSOCIACAO MEDICA BRASILEIRA
Science Citation Index Expanded, Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, Directory of Open Access Journals
Aspirin, Clopidogrel, Drug resistance, Acute coronary syndrome, Atrial fibrillation, C-REACTIVE PROTEIN, ANTITHROMBOTIC THERAPY, PERCUTANEOUS CORONARY, MYOCARDIAL-INFARCTION, ANTICOAGULATION, MANAGEMENT, INTERVENTION, INFLAMMATION, CLOPIDOGREL, STRATEGIES
In patients with atrial fibrillation, standard anticoagulation with a vitamin K antagonist plus dual antiplatelet therapy with a P2Y12 inhibitor and aspirin is the standard of care after percutaneous coronary intervention (PCI). While this therapy reduces the risk of thrombosis and stroke, it increases the risk of bleeding. It is unclear whether the antiplatelet effect of aspirin and clopidogrel may worsen atrial fibrillation (AF).